High-sensitivity cardiac troponin and the under diagnosis of myocardial infarction in women: a prospective cohort study
|
|
|
- Edward Walsh
- 5 years ago
- Views:
Transcription
1 DATA SUPPLEMENT High-sensitivity cardiac troponin and the under diagnosis of myocardial infarction in women: a prospective cohort study Anoop SV Shah, 1 Megan Griffiths, 1 Kuan Ken Lee, 1 David A McAllister, 2 Amanda L Hunter, 1 Anne Cruikshank, 3 Alan Reid, 3 Mary Stoddart, 4 Fiona Strachan, 1 Simon Walker, 4 Paul O Collinson, 5 Fred S Apple, 6 Alasdair J Gray, 7 Keith AA Fox, 1 David E Newby 1 and Nicholas L Mills 1 1 BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom 2 Centre for Population Health Sciences, University of Edinburgh, United Kingdom 3 Department of Biochemistry, Southern General Hospital, United Kingdom 4 Department of Biochemistry, Royal Infirmary of Edinburgh, United Kingdom 5 Department of Cardiology, St George s Hospital and Medical School, United Kingdom 6 Department of Laboratory Medicine and Pathology, University of Minnesota, United States of America 7 Department of Emergency Medicine, Royal Infirmary of Edinburgh, United Kingdom Correspondence and requests for reprints: Dr Nicholas L Mills BHF/University Centre for Cardiovascular Science Chancellor s Building University of Edinburgh Edinburgh EH16 4SB United Kingdom Tel: Fax: nick.mills@ed.ac.uk Support: British Heart Foundation Special Project Grant (SP/12/10/29922), Clinical Research Scholarship (SS/CH/09/002), Intermediate Fellowship (FS/10/024/28266) and Chair Award (CH/09/002). Table and Figures: 4 1
2 Table S1. Diagnosis of myocardial infarction using contemporary and high-sensitivity assays Contemporary assay a High-sensitivity assay (single threshold) b High-sensitivity assay P-value d P-value e (sex-specific threshold) c All patients (n=1,126) Type 1 myocardial infarction 172 (15%) 222 (20%) 242 (21%) < Type 2 myocardial infarction 47 (4%) 55 (5%) 56 (5%) Myocardial injury 27 (2%) 38 (3%) 40 (4%) < Unstable angina 38 (3%) 28 (2%) 28 (2%) Other 842 (75%) 783 (70%) 760 (68%) < Men (n=622) Type 1 myocardial infarction 117 (19%) 142 (23%) 131 (21%) Type 2 myocardial infarction 27 (4%) 30 (5%) 28 (5%) Myocardial injury 12 (2%) 15 (2%) 12 (2%) Unstable angina 27 (4%) 20 (3%) 22 (4%) Other 439 (71%) 415 (67%) 429 (69%) Women (n=504) Type 1 myocardial infarction 55 (11%) 80 (16%) 111 (22%) <0.001 <0.001 Type 2 myocardial infarction 20 (4%) 25 (5%) 28 (6%) Myocardial injury 15 (3%) 23 (5%) 28 (6%) < Unstable angina 11 (2%) 8 (2%) 6 (1%) Other 403 (80%) 368 (73%) 331 (66%) <0.001 <0.001 a. Contemporary assay single threshold 50 ng/l b. High-sensitivity assay single threshold 26 ng/l c. High-sensitivity assay sex-specific thresholds: women 16 ng/l and men 34 ng/l d. McNemar s test comparing diagnosis based on high-sensitivity troponin assay using sex-specific thresholds to the contemporary assay using a single threshold e. McNemar s test comparing diagnosis based on high-sensitivity troponin assay using sex-specific thresholds to the high-sensitivity assay using a single threshold 2
3 3
4 Table S2. Baseline characteristics of women with and without myocardial infarction where assays were concordant (groups 3 and 1 respectively) and those only identified using the high-sensitivity assay with sex-specific thresholds (group 2)* Group 1 n=337 Group 2 n=56 Group 3 n=55 Age 65 (16) 76 (12) 75 (15) Chest pain 264 (79) 42 (75) 48 (87) Risk Factors Smoker 57 (19) 10 (20) 8 (15) Hypertension 165 (49) 36 (64) 31 (56) Hyperlipidaemia 135 (40) 28 (50) 20 (36) Diabetes mellitus 43 (13) 11 (20) 9 (16) Past medical history Ischaemic heart disease 124 (37) 34 (61) 17 (31) Myocardial infarction 56 (17) 23 (41) 13 (24) Ischaemic stroke 15 (4) 7 (12) 5 (9) Transient ischaemic attack 21 (6) 1 (2) 3 (5) Peripheral vascular disease 2 (1) 0 (0) 3 (5) Revascularisation Previous PCI 32 (10) 7 (12) 7 (13) Previous CABG 12 (4) 5 (9) 2 (4) Haemodynamics Systolic pressure, mmhg 137 (25) 137 (30) 138 (30) Diastolic pressure, mmhg 71 (14) 71 (17) 75 (18) Heart rate, beats per minute 77 (18) 83 (21) 84 (18) Clinical chemistry Haemoglobin, g/dl 130 (56) 127 (15) 125 (17) Creatinine, mg/dl 72 (23) 90 (38) 95 (49) Urea, mg/dl 6 (6) 9 (8) 7 (4) Cholesterol, mmol/l 5 (1) 5 (1) 5 (1) Electrocardiography ST elevation 9 (3) 5 (9) 16 (30) ST depression 23 (7) 11 (20) 13 (24) T wave inversion 63 (20) 15 (27) 12 (22) Admission drugs Aspirin, n (%) 109 (33) 29 (54) 20 (36) Clopidogrel, n (%) 37 (11) 9 (17) 4 (7) B-blockers, n (%) 83 (25) 22 (41) 14 (25) ACE inhibitors, n (%) 89 (27) 21 (39) 23 (42) Statins, n (%) 123 (37) 30 (56) 20 (36) Warfarin, n (%) 15 (5) 7 (13) 3 (5) Proton pump inhibitor, n (%) 119 (36) 26 (48) 20 (36) *Excludes patients adjudicated as type 2 myocardial infarction or myocardial injury 4
5 Table S3. Baseline characteristics of men with and without myocardial infarction where assays were concordant (groups 3 and 1 respectively) and those only identified using the high-sensitivity assay with sex-specific thresholds (group 2)* Group 1 n=451 Group 2 n=14 Group 3 n=117 Age 61 (15) 64 (17) 67 (14) Chest pain, n (%) 383 (85) 14 (100) 99 (85) Risk Factors Smoker, n (%) 145 (34) 6 (46) 38 (34) Hypertension, n (%) 227 (50) 7 (50) 61 (53) Hyperlipidaemia, n (%) 210 (47) 9 (64) 54 (47) Diabetes mellitus, n (%) 69 (15) 3 (21) 25 (22) Past medical history Ischaemic heart disease, n (%) 193 (43) 9 (64) 54 (47) Myocardial infarction, n (%) 135 (30) 8 (57) 33 (28) Ischaemic stroke, n (%) 38 (8) 3 (21) 8 (7) Transient ischaemic attack, n (%) 20 (4) 0 (0) 3 (3) Peripheral vascular disease, n (%) 12 (3) 1 (7) 8 (7) Revascularisation Previous PCI, n (%) 93 (21) 4 (29) 18 (16) Previous CABG, n (%) 40 (9) 2 (14) 14 (12) Haemodynamics Systolic pressure, mmhg 133 (22) 141 (23) 131 (22) Diastolic pressure, mmhg 73 (15) 75 (14) 74 (14) Heart rate, beats per minute 78 (18) 78 (15) 81 (22) Clinical chemistry Haemoglobin, g/dl 141 (17) 142 (24) 138 (21) Creatinine, mg/dl 82 (24) 133 (197) 104 (57) Urea, mg/dl 6 (3) 7 (6) 7 (4) Cholesterol, mmol/l 4 (1) 5 (1) 5 (1) Electrocardiography ST elevation, n (%) 36 (8) 1 (8) 42 (36) ST depression, n (%) 13 (3) 1 (8) 29 (25) T wave inversion, n (%) 75 (17) 3 (23) 34 (29) Admission drugs Aspirin, n (%) 178 (40) 9 (64) 46 (40) Clopidogrel, n (%) 55 (12) 5 (36) 12 (11) Beta-blockers, n (%) 119 (27) 8 (57) 34 (30) ACE inhibitors / ARB, n (%) 149 (34) 5 (36) 38 (33) Statin, n (%) 194 (44) 8 (57) 52 (45) Warfarin, n (%) 28 (6) 1 (7) 6 (5) Proton pump inhibitor, n (%) 139 (31) 6 (43) 31 (27) *Excludes patients adjudicated as type 2 myocardial infarction or myocardial injury 5
6 6
7 Figure S1. Distribution of troponin and upper reference limits (99th percentile) in 4,590 samples from healthy men and women Reference population consists of 1,531 persons with an equal number of men and women. Inclusion criteria were age 21 to 75 years, no previous medical illness, normal renal function (egfr >60 ml/min), glycated haemoglobin (HbA1c) 6% and normal B-type naturetic peptide concentrations (male 25 pg/ml and female 40 pg/ml) (Rogers et al Clin Chem; 2013 (10) A225). 7
Improving the detection of myocardial infarction in women
Improving the detection of myocardial infarction in women British Cardiac Society Listening to the Female Voice 4 th June 2014 anoopsshah@gmail.com Dr Anoop Shah BHF Centre for Cardiovascular Sciences
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Shah ASV, Anand A, Strachan FE, et al. High-sensitivity
High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study
High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study Anoop S V Shah*, Atul Anand*, Yader Sandoval, Kuan Ken Lee, Stephen W Smith, Philip
CLINICAL RESEARCH STUDY
CLINICAL RESEARCH STUDY Sensitive Troponin Assay and the Classification of Myocardial Infarction Anoop S.V. Shah, MD, a David A. McAllister, MD, b Rosamund Mills, MD, a Kuan Ken Lee, MD, a Antonia M.D.
Edinburgh Research Explorer
Edinburgh Research Explorer Sensitive Troponin Assay and the Classification of Myocardial Infarction Citation for published version: Shah, AS, McAllister, DA, Mills, R, Lee, KK, Churchhouse, AM, Fleming,
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David
High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study
open access High sensitivity cardiac troponin and the under-diagnosis of myocardial in women: prospective cohort study Anoop S V Shah, 1 Megan Griffiths, 1 Kuan Ken Lee, 1 David A McAllister, 2 Amanda
SUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
Troponin when is an assay high sensitive?
Troponin when is an assay high sensitive? Professor P. O. Collinson MA MB BChir FRCPath FRCP edin MD FACB EurClin Chem Consultant Chemical Pathologist and Professor of Cardiovascular Biomarkers, Departments
High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial
EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2018 High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial Professor
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery
EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2010 FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery Nicholas L Mills, David A McAllister, Sarah Wild, John D MacLay,
Supplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
Ulster, Ireland. Submitted: 21 June 2009; Revised: 24 January 2010; Published: 13 September 2010 Petrazzuoli F, Soler JK, Buono N, Dobbs F
O R I G I N A L R E S E A R C H Quality of care for hypertensive patients with type 2 diabetes in a rural area of Southern Italy: is the recording of patient data and the achievement of quality indicators
Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
egfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
Diagnostic and prognostic benefits of CTCA using the 2016 NICE guidance within a randomised trial
SUPPLEMENTARY APPENDIX Diagnostic and prognostic benefits of CTCA using the 2016 NICE guidance within a randomised trial Philip D. Adamson* 1, Amanda Hunter* 1, Michelle C. Williams 1,2, Anoop S.V. Shah
Cardiovascular risk reduction in diabetes Lipids (NICE CG181)
Cardiovascular risk reduction in diabetes Lipids (NICE CG181) Primary Prevention T1DM Offer Atorvastatin 20mg if >40 years old Diabetes duration >10 years Established nephropathy Other CVS risk factors
Recent community campaigns on
Availability of highly sensitive troponin assays and acute coronary syndrome care: insights from the SNAPSHOT registry Use of hs troponin testing of patients hospitalised with possible ACS was associated
DECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
What is a myocardial infarction and how do we treat it? Paul Das Consultant Cardiologist North Wales Cardiac Centre Glan Clwyd Hospital
What is a myocardial infarction and how do we treat it? Paul Das Consultant Cardiologist North Wales Cardiac Centre Glan Clwyd Hospital What is a myocardial infarction? THEY AINT WHAT THEY USED TO BE Case
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
Patient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
Chronic Benefit Application Form Cardiovascular Disease and Diabetes
Chronic Benefit Application Form Cardiovascular Disease and Diabetes 19 West Street, Houghton, South Africa, 2198 Postnet Suite 411, Private Bag X1, Melrose Arch, 2076 Tel: +27 (11) 715 3000 Fax: +27 (11)
European Heart Journal 2015 doi: /eurheartj/ehv320
European Heart Journal 2015 doi: 10.1093/eurheartj/ehv320 1 2 Clinical implications of high-sensivity troponin assays European Heart Journal 2015 doi: 10.1093/eurheartj/ehv320 Conditions other than Type
Coronary Heart Disease
Coronary Heart Disease This document is a final specification of the PRIMIS Comparative Analysis Service (CAS) MIQUEST query set to enable analyses in support of the NSF for CHD. The specification has
Lowering blood pressure (BP) in patients with type 2
Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial William B. White, MD; Fatima Jalil, MD;
APPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Martin Landray and Louise Bowman on behalf of the HPS 3 / TIMI 55 - REVEAL Collaborative
Cardiology. Self Learning Package. Module 5: Pharmacology: Treatment of Acute Coronary. Prevention
Cardiology Self Learning Package Module 5: Pharmacology: Treatment of Acute Coronary Syndromes, Module 5: Pharmacology: Hyperlipidaemia, Treatment of Acute Coronary Hypertension, Symdrome, Hyperlipidaemia,
The Author(s) This article is published with open access by ASEAN Federation of Cardiology
DOI 10.7603/s40602-014-0011-3 ASEAN Heart Journal http://www.aseanheartjournal.org/ Vol. 22, no. 1, 60 65 (2014) ISSN: 2315-4551 Erratum Erratum to: Impact Of Sex On Clinical Characteristics And In-Hospital
Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI
Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the
Toledo Hospital Clinical Quality Indicators. Effective - Heart Attack
Effective - Heart Attack This page shows information on effective measures for patients who had heart attacks. "Effective care" means patients are given treatments that scientific evidence has shown leads
Defining rise and fall of cardiac troponin values
Defining rise and fall of cardiac troponin values Doable but Not Simple Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for Artery, Atrial Fibrillation, Hypertension
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
Cardiology Department Coimbra Hospital and Medical School Portugal
Quantitative troponin elevation provide incremental prognostic value beyond comprehensive risk stratification in patients with acute coronary syndromes. Rui Baptista, Elisabete Jorge, Hélia Martins, Fátima
6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS
PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient
The ESC Registry on Chronic Ischemic Coronary Disease
EURObservational Research Programme The ESC Registry on Chronic Ischemic Coronary Disease Prof. Fausto J. Pinto, FESC, FACC, FASE, FSCAI Immediate Past-President, ESC University Hospital Sta Maria University
Troponin Assessment. Does it Carry Clinical Message? Stefan Blankenberg. University Heart Center Hamburg
Biomarkers for Optimal Management of Heart Failure Troponin Assessment Does it Carry Clinical Message? Stefan Blankenberg University Heart Center Hamburg Congress of the European Society of Cardiology
Preventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to
HFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol)
CLINICAL GUIDELINE Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol) A guideline is intended to assist healthcare professionals in the choice of disease-specific
LIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
Treatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
Inter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
Quality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
CVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
Long-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
Early discharge in selected patients after an acute coronary syndrome can it be safe?
Early discharge in selected patients after an acute coronary syndrome can it be safe? Glória Abreu, Pedro Azevedo, Carina Arantes, Catarina Quina-Rodrigues, Sara Fonseca, Juliana Martins, Catarina Vieira,
Protecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation Thierry Gillebert European Society of Cardiology, Slides kindly provided
Practice-Level Executive Summary Report
PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher,
Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
Preoperative tests (update)
National Institute for Health and Care Excellence. Preoperative tests (update) Routine preoperative tests for elective surgery NICE guideline NG45 Appendix C: April 2016 Developed by the National Guideline
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
Jin Wi, 1 Young-Guk Ko, 1 Jung-Sun Kim, 1 Byeong-Keuk Kim, 1 Donghoon Choi, 1 Jong-Won Ha, 1 Myeong-Ki Hong, 1,2 Yangsoo Jang 1,2 ORIGINAL ARTICLE
See Editorial, p 1723 1 Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Republic of Korea 2 Severance Biomedical Science Institute, Yonsei University
Quality Payment Program: Cardiology Specialty Measure Set
Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor
Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a sensitive troponin I assay
Original Article Annals of Clinical Biochemistry 2015, Vol. 52(5) 543 549! The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: 10.1177/0004563215576976 acb.sagepub.com
Hypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
Update on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
Sheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017)
Sheffield guidelines f the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017) Approved by Sheffield Area Prescribing Committee and Sheffield Teaching Hospitals
Impact of Aging on High-sensitivity Cardiac Troponin T in Patients Suspected of Acute Myocardial Infarction
doi: 10.2169/internalmedicine.8510-16 http://internmed.jp ORIGINAL ARTICLE Impact of Aging on High-sensitivity Cardiac Troponin T in Patients Suspected of Acute Myocardial Infarction Taro Ichise, Hayato
Post Operative Troponin Leak: David Smyth Christchurch New Zealand
Post Operative Troponin Leak: Does It Really Matter? David Smyth Christchurch New Zealand Life Was Simple Once Transmural Infarction Subendocardial Infarction But the Blood Tests Were n t Perfect Creatine
Sample Submission Form Hypertension in childhood and adolescence
Sample Submission Form Hypertension in childhood and adolescence Physician Name: Specialty: Clinic / Practice: Street Address: Postal Code: City: Country: Phone: Fax: Email: Patient Information Surname,
Primary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
IFCC Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) Report to the General Conference 2016 Madrid
IFCC Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) Report to the General Conference 2016 Madrid 1 CREATED By the EB in 2011, following to the Committee on Standardization of Cardiac
Non ST Elevation-ACS. Michael W. Cammarata, MD
Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar
Andreas Baumbach Bristol Heart Institute Bristol Royal Infirmary. London 27/1/2005
Andreas Baumbach Bristol Heart Institute Bristol Royal Infirmary AB London 27/1/2005 Revascularisation in ACS ICTUS MERLIN REACT 4mins 4mins 4mins AB Tony s Comments 15mins ICTUS Comparison of an early
ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
Evaluation of a diagnostic pathway in heart failure in primary care, using electrocardiography and brain natriuretic peptide guided echocardiography
Evaluation of a diagnostic pathway in heart failure in primary care, using electrocardiography and brain natriuretic peptide guided echocardiography Rebecka Karlsson Pardeep Jhund 1 Material and methods
14/15 Threshold 15/16 Points 15/16. Points. Retired Replaced by NM82/AF007. Replacement NO CHANGE
SUMMARY OF CHANGES TO QOF 2015/1 - ENGLAND KEY No change Retired/replaced Wording and/or change Point or threshold change Indicator ID change 14/15 QOF ID 15/1 QOF ID NICE ID Indicator wording Changes
Supplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD
Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD Disclosures Research contracts: AstraZeneca, Bayer, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company,
How Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
Cardiovascular Concerns in Intermediate Care
Cardiovascular Concerns in Intermediate Care GINA ST. JEAN RN, MSN, CCRN-CSC CLINICAL NURSE EDUCATOR HEART AND & CRITICAL AND INTERMEDIATE CARE Objectives: Identify how to do a thorough assessment of the
Characteristics of Transient ST-Elevation versus ST-Elevation and Non-ST-Elevation Myocardial Infarction
Characteristics of Transient ST-Elevation versus ST-Elevation and Non-ST-Elevation Myocardial Infarction Blondheim DS, Shochat M, Asif A, Kazatsker M, Frimerman A, Vassilenko L, Abu Fane R, Neiman E, Barel
Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital
Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke
STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION
STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION Otávio Berwanger, MD, FACS - On behalf of the SECURE Steering Committee and Investigators Trial Organization Trial Steering Committee Dr.
Preoperative Cardiac Risk Assessment: Approach & Guidelines
Preoperative Cardiac Risk Assessment: Approach & Guidelines By, Liam Morris, MD., FACC (02/03/18) CPG : Clinical Practice Guidelines GDMT : Guidelines Directed Medical Therapy GWC : Guideline Writing Committee
Cardiovascular Disease in Women -Vive La Difference? Dr Homeyra Douglas Consultant Cardiologist Aintree University Hospital
Cardiovascular Disease in Women -Vive La Difference? Dr Homeyra Douglas Consultant Cardiologist Aintree University Hospital Death By Cause - Women 2004 UK Death by Cause-Women 2004 UK -CVD is responsible
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
Condition/Procedure Measure Compliance Criteria Reference Attribution Method
Premium Specialty: Cardiology Credentialed Specialties include: Cardiac Diagnostic, Cardiology, Cardiovascular Disease, Clinical Cardiac Electrophysiology, and Interventional Cardiology This document is
Diabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
The contractor establishes and maintains a register of patients with AF
Atrial Fibrillation The contractor establishes and maintains a register of patients with AF G5731 Those patients with AF in whom there is a record of CHADS2 score of 1, the % of patients who are currently
D M Y Y Y Y D D M M Y Y Y Y. Previous MI (apart from acute PCI) 0=no 1=yes 9=unknown
I Patient details and Preoperative Data Date of Informed Consent dd-mm-yyyy (Please leave blank if waived by Ethics Committee) Please enter Patient ID in this format xxx-xx-xxx 3 digit code for the country,
Unstable angina and NSTEMI
Issue date: March 2010 Unstable angina and NSTEMI The early management of unstable angina and non-st-segment-elevation myocardial infarction This guideline updates and replaces recommendations for the
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Shah AD, Langenberg C, Rapsomaniki E, et al.